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INTRODUCTION
Oral antiviral agents are currently available and are the main
option for the treatment of patients with chronic hepatitis B.
In a large proportion of patients, antiviral therapy can slow
down the disease progression by hepatitis B virus (HBV) DNA
suppression and hepatitis ‘e’ antigen (HBeAg) seroconversion.
However, the potential emergence of drug resistant mutations
remains a caveat of oral antivirals; mutations increase as the
treatment duration extends (1, 2). In addition, mutations to
one drug may lead to resistance to other drugs. Patients with
lamivudine (LMV)-resistant rtM204I/V (±rtL180M) muta-
tions in the catalytic tyrosine-methionine-aspartate-aspartate
(YMDD) motif are less responsive to entecavir (ETV) (1, 2).
Among adefovir (ADV) treated patients, rtA181T or rtA181V
mutations have been associated with a 2-6 fold decrease in
sensitivity to LMV (2).
Mutation of the HBV polymerase can alter the amino acid
codon of the surface genes and vice versa, because the poly-
merase gene, the main target of antiviral drug resistant muta-
tions, has overlapping reading frames with the surface region
(1, 3). In LMV treated patients, the P120A mutation in the
S region results in hepatitis B surface antigen (HBsAg) detec-
tion failure (4). Lee et al. (5) reported overlapping surface gene
mutations of HBV in an LMV-treated patient who finally lost
HBsAg. In this patient, they detected deletions of nucleo-
tides 23 to 55 (amino acids 12 to 22) in the Pre-S2 region,
and amino acid substitutions at I126S, T131N, M133T, and
S136Y in the ‘a’ determinant region of HBsAg.
Overlap of surface gene mutations, such as sW172stop in
patients carrying rtA181T, and sL173F in patients carrying
rtA181V, have been reported in chronic hepatitis B patients
receiving ADV treatment. However, the clinical consequences
of these changes have not been determined (1, 2). The goal of
this study was to evaluate the surface gene sequence in ADV-
resistant patients carrying A181T/V mutations and to deter-
mine the associated clinical significance.
MATERIALS AND METHODS
Patients
Twenty-two patients with chronic hepatitis B were includ-
ed in this study. Nine patients had not been previously treat-
ed with antiviral agents and thus formed the control group
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Hepatitis B Viral Surface Mutations in Patients with Adefovir Resistant
Chronic Hepatitis B with A181T/V Polymerase Mutations
The hepatitis B virus (HBV) polymerase gene has overlapping reading frames with
surface genes, which allows to alter the amino acid codon of the surface genes. In
adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V muta-
tions, overlap with surface gene mutations such as sW172stop/sL173F has been
reported. However, the clinical consequences of such surface mutations have not
been determined. The aim of this study was to determine the surface gene sequence
in ADV-resistant patients carrying the A181T/V mutation and to describe the clini-
cal significance. Of the 22 patients included in this study, 13 were ADV-resistant
with rtA181T/V mutations (polymerase mutation group, Group P) and nine were
antiviral treatment-naive (control group, Group C). The Pre-S1 gene mutation, V60A,
was detected in 11 patients (Group P=8, Group C=3). A start codon mutation in the
Pre-S2 gene was found in five patients (Group P=3, Group C=2). An S gene mutation,
sA184V, was found in nine patients, all of whom were in group P. Although sW172stop
and sL173F mutations were detected, reduced HBsAg titer was not observed. Fur-
ther study of these mutations and their clinical implications are needed.
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. .(nucleos[-t]ide naive patients, Group C). The remaining thir-
teen patients were ADV-resistant, having an rtA181T muta-
tion, rtA181V mutation, or both mutations (ADV polymerase
mutation group, Group P). These patients developed ADV
resistance while undergoing ADV monotherapy as rescue ther-
apy for LMV-resistant HBV (rtM204I/V±rtL180M). The
ADV-resistant mutations were detected using restriction frag-
ment mass polymorphism (RFMP) method as previously des-
cribed (6). Serum was collected from the patients every two
to three months during treatment and was kept at -20℃until
the mutation analyses were performed. The serum collected
at the time of ADV-resistant rtA181T/V mutation detection
was used for sequencing analysis. Informed consent was ob-
tained from each patient and the experimental protocol was
approved by the Korea University Guro Hospital Human
Research Committee.
Biochemical and virology monitoring 
At the time of serum collection, we conducted routine full
blood examinations and liver function tests, including tests
for aspartate aminotransferase (AST), alanine aminotransferase
(ALT), total bilirubin, albumin, prothrombin time, blood
urea nitrogen (BUN), and creatinine. HBsAg and antibody
to the HBs antigen were measured using the commercially
available radioimmunoassay kits (Abbot Laboratories, North
Chicago, IL, USA). The HBsAg titer was measured using
the chemiluminescent microparticle immunoassay (CMIA)
ARCHITECT
� HBsAg assay (Abbot Laboratories). HBeAg
and antibody to the HBe antigen were measured using com-
mercially available radioimmunoassay kits (Shin Jin Medics
Inc., Goyang, Korea). HBV-DNA was quantified using the
Hybrid Capture II assay (Digene Diagnostics Inc., Beltsville,
MD, USA) or the VERSANT
� HBV DNA 3.0 assay (Sie-
mens Healthcare Diagnostics Inc., Tarrytown, NY, USA) and
data showed ‘pg/mL’ were converted to ‘copies/mL’ (1 pg=
283,000 copies).
Polymerase chain reaction
Hepatitis B viral DNA was extracted from 200 mL of serum
using the QIAamp
� MinElute
� Virus Spin kit (Qiagen Inc.,
Vanencia, CA, USA) according to the manufacturer’s instruc-
tions. The S coding region of HBV was amplified using HBS-
1S (the forward primer) and HBS-1AS (the backward primer)
as previously described (5). The amplification conditions con-
sisted of 94℃ for 3 min, 35 cycles of 94℃ for 30 sec, and
55℃ for 30 sec. This was followed by a final primer exten-
sion at 72℃for 1 min using the Taq PCR Core Kit (Qiagen
Inc.). The polymerase chain reaction (PCR) amplified HBV
DNA was purified using the QIAquick
� PCR Purification
Kit (Qiagen Inc.) according to the manufacturer’s instructions.
Sequencing
The primers used for direct sequencing were HBS-1S, HBS-
1AS, HBS-2S, and HBS-3S as previously described (5). Sequ-
encing reactions were performed in an MJ Research PTC-
225 Peltier Thermal Cycler using an ABI PRISM BigDyeTM
Terminator Cycle Sequencing Kit with AmpliTaq DNA poly-
merase (Applied Biosystems Inc., Foster, CA, USA) accord-
ing to the manufacturer’s instructions. Single-pass sequenc-
ing was performed on each template using the aforemention-
ed primers. The fluorescent-labeled fragments were purified
from the unincorporated terminators with an ethanol precipi-
tation protocol. The samples were resuspended in distilled
water and subjected to electrophoresis in an ABI PRISM
3730XL Analyzer (Applied Biosystems Inc.).
Analysis
The nucleotide sequences were compared with those of
the HBV genotype C subtype ‘adr’ registered at the Nation-
al Center for Biotechnology Information (NCBI, nucleotide
LOCUS AF286594). The genotype of the obtained HBV
DNA sequences was determined by a web-based genotyp-
ing tool for viral sequences at the NCBI (7). 
Statistical analysis
We conducted the Fisher’s exact tests for categorical vari-
ables and Mann-Whitney’s U-tests for continuous variables
to compare patients with the rtA181T/V mutation to those
without the rtA181T/V mutation. Values are expressed as
median (range). A P value <0.05 was considered statistical-
ly significant.
RESULTS
Demographic and biochemical characteristics 
Demographic and biochemical data are summarized in
Table 1. Among the 13 patients in Group P, the majority
were males (n=10). All patients in Group C were males. Bio-
chemical data are represented as median (range) (median of
Group P vs. Group C, P value). Group P was significantly
older than Group C, 45 (28-75) (47 vs. 39, P=0.025), had
higher levels of albumin 4.2 (2.5-5) (4.2 vs. 3.6, P>0.05).
Group P also had lower levels of AST 100.5 (23-385) (65
vs. 193, P=0.001), ALT 155 (22-385) (78 vs. 262, P<0.001),
and total bilirubin 1.1 (0.4-33.6) (1.0 vs. 1.3, P>0.05). Ten
of the 22 patients had liver cirrhosis (LC) (Group P=7, Group
C=3). Thirteen of the 22 patients were HBeAg positive (Group
P=7, Group C=6). Two cases of hepatocellular carcinoma
(HCC) were included (Group P=1, Group C=1).
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ADV, adefovir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CH, chronic


















C1 - Male 33 - 7.7 260/290 2.2 3.6 CH
C2 - Male 40 + 7.9 253/325 0.8 2.5 LC with ascites
C3 - Male 39 + 7.8  224/170 3.9 2.5 LC with ascites
C4 - Male 34 + 8.0 125/262 0.7 4.5 CH
C5 - Male 28 + 8.3 75/169 0.9 4.4 CH
C6 - Male 30 + 7.9 103/262 1.0 4.7 CH
C7 - Male 75 - 8.6 385/249 3.4 2.6 LC
C8 - Male 51 - 8.1 190/178 33.6 3.1 HCC
C9 - Male 43 + 9.2 193/319 1.3 4.5 CH
P1 A181T Female 57 - 6.3 273/110 3.1 2.8 LC with ascites
P2 A181T Male 57 + 6.2 40/30 1.5 3.7 HCC
P3 A181T Female 50 + 5.8 67/47 1.9 3.3 LC
P4 A181T Male 45 + 7.9 75/63 3.0 3.3 LC with ascites
P5 A181T Female 70 + 6.3 64/73 0.4 4.2 CH
P6 A181V Male 40 - 5.8 64/156 0.4 4.7 LC
P7 A181V Male 46 - 4.1 29/22 0.9 3.0 LC
P8 A181T Male 41 + 7.0 23/34 1.4 4.8 CH
P9 A181T Male 45 - 7.9 40/78 1.0 4.7 CH
P10 A181V Male 57 + 8.0 118/96 1.0 4.7 LC
P11 A181T Male 49 - 7.7 101/154 0.9 4.1 CH
P12 A181T/V Male 43 + 7.5 65/96 1.2 5.0 CH
P13 A181V Male 47 - 6.9 100/232 0.9 4.8 LC
Table 1. Patients’ demographic, biochemical and clinical characteristics
Number of point mutations








C1 C adr 2,075 6 3 2 11
C2 C adr 12,335 2 8 8 18
C3 C adr 24,205 2 0 3 5
C4 C adr 8,850 2 2 1 5
C5 C adr 50,660 4 5 1 10
C6 C adr 15,090 2 4 0 6
C7 C adr 18,250 3 2 6 11
C8 C adr 2,490 4 4 2 10
C9 C adr 24,770 3 0 3 6
Median (range) of Group C 15,090 (2,075-50,660) 3 (2-6) 3 (0-8) 2 (0-8) 10 (5-18)
P1 C adr 2,010 5 1 6 12
P2 C adr 4,530 3 6 9 18
P3 C adr 960 4 1 1 6
P4 C adr 6,330 4 2 2 8
P5 C adr 6,055 0 1 1 2
P6 C adr 5,605 3 0 4 7
P7 C adr 2,340 1 0 4 5
P8 C adr 98,440 2 0 2 4
P9 C ayr 37,590 3 0 3 6
P10 C adr 21,385 4 1 6 11
P11 C adr 5,175 3 2 5 10
P12 C adr 14,280 4 0 4 8
P13 C adr 5,950 2 2 4 8
Median (range) of Group P 5,950 (960-98,440) 3 (0-5) 1 (0-6) 4 (1-9) 8 (2-18)
Total 7,590 (960-98,440) 3 (0-6) 1.5 (0-8) 3 (0-9) 8 (2-18)
Group C vs. Group P P=0.235 P=0.487 P=0.133 P=0.413 P=0.583
Table 2. Genotype, HBsAg subtype, HBsAg titer and point mutations
HBsAg, hepatitis B surface antigen.HBV genotype, subtype, and point mutations
All patients in our study were infected with HBV geno-
type C. Twenty-one of the 22 patients had the ‘adr’ subtype
and one patient had the ‘ayr’ subtype. For the Pre-S1, Pre-
S2, and S genes, the incidence of mutations in Group P and
Group C were 3 vs. 3 (P>0.05), 1 vs. 3 (P>0.05), and 4 vs.
2 (P>0.05), respectively. The median number of point muta-
tions in the entire region was 8 (Group P=8, Group C=10,
P>0.05). Most cases had mutations in the S gene except for
one case in Group C. One patient in Group P did not have
a mutation in the Pre-S1 gene and seven patients (Group P=5,
Group C=2) had no mutations in the Pre-S2 gene (Table 2).
Changes in the serum hepatitis B surface antigen titer
We conducted serum HBsAg titers to evaluate the clini-
cal consequences of the surface gene mutation. The median
HBsAg titer was 7,590 IU/mL (Group P=5,950, Group
C=15,090, P>0.05). There was no significant difference,
regardless of whether they harbored the rtA181T/V muta-
tion (Table 2).
Pre-S1 region
In the Pre-S1 region, 12 patients (six cases in each group)
had nucleotide deletions at position ‘21’ (amino acid [a.a.]
7) and 18 patients (nine cases in each group) had nucleotide
deletions at position ‘30’ (a.a. 10). Nucleotide deletions at
position ‘59’ (a.a. 20) were detected in 5 of 13 patients in
Group P and 2 of 9 patients in Group C. An H51Q muta-
tion was detected in two patients (one case in each group).
Eight of 13 patients in Group P and 3 of 9 patients in Group
C had a V60A mutation. G2A (n=1), G73D (n=1), L74I
(n=2), A91T (n=1), and A95T (n=1) mutations were detect-
ed in Group P. In Group C, A81T (n=1), T86A (n=2), and
A95V (n=1) mutations were detected. Three cases of I84T
mutations were found in Group C, compared to only one in
Group P (Fig. 1).
Pre-S2 region
A start codon mutation was identified in five patients
(Group P=3, Group C=2) in the Pre-S2 gene. All five pati-
ents with this mutation had cirrhosis, and two of these pati-
ents also had HCC (Group P=1, Group C=1). V32A, I45T,
and T49I mutations were detected in the patients with HCC,
both groups equally. An F46S mutation was observed in Group
P (n=2); a Q2K mutation in Groups P (n=1) and C (n=1);
an A11T mutation in Groups P (n=2) and C (n=1); and an
F22L mutation in Groups P (n=2) and C (n=2).
In Group C, there was one case of each of the following
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Fig. 1. Sequence changes in the Pre-S1 regions. Twelve patients
(six cases in each group) and 18 patients (nine cases in each
group) had nucleotide deletions at positions ‘21’ and ‘30’. Nucleo-
tide deletions at position ‘59’ were detected in 5 of 13 patients in
Group P and in 2 of 9 patients in Group C. An H51Q mutation was
detected in two patients (one case in each group). A V60A muta-
tion was detected in 8 of 13 patients in Group P and 3 of 9 patients
in Group C. L74I mutations in Group P (n=2) and T86A mutations
in Group C (n=2) were detected. Three cases of an I84T mutation
were found in Group C and one case in Group P. G2A, G73D, A91T,
and A95T mutations were detected in Group P. A81T and A95V
mutations were detected in Group C.
Fig. 2. Sequence changes in the Pre-S2 regions. Five start codon
mutations were identified in the Pre-S2 region. V32A, I45T and T49I
mutations were detected in HCC cases. Q2K (Group P=1, Group
C=1), A11T (Group P=2, Group C=1), F22L (Group P=2, Group
C=2), and F46S (Group P=2) mutations were observed. In Group
C, there were following mutations: N4K, T7A, H9Q, R16P, R16G,
V17P, V17A, R18S, G19S, L20Q, P54Q, nucleotide ‘418-423’ dele-
tion, ‘419’ deletion, and ‘425’ deletion. In Group P, one case each
of I42T, P54L mutation and nucleotide 406 deletion were detected.mutations: N4K, T7A, H9Q, R16P, R16G, V17P, V17A,
R18S, G19S, L20Q, P54Q, nucleotide 418-423 deletion (a.a.
21-22), 419 deletion (a.a. 21), and 425 deletion (a.a. 23). In
Group P, mutations I42T, P54L, and nucleotide 406 dele-
tion (a.a. 17) were detected (Fig. 2).
S region
Among the patients in Group P, sW172stop (n=5) and
sL173F (n=5) mutations were detected. In the S gene, an
A184V mutation was found in 9 of 13 patients in Group P.
However, it was not detected in Group C (P=0.002). Other
mutations that we detected in the S gene include S3N (Group
P=4, Group C=2), I68T (Group P=3, Group C=1), I126T
(Group P=4, Group C=1), and L213I (Group P=6, Group
C=1). These mutations were most frequent in Group P.
In Group C, there was one case of each of the following
mutations: G10stop, L15V, I28V, W36L, F41S, T47A, Q51L,
N59H, C69stop, L87V, F93L, V96G, L97P, G102C, T131P,
Y200F, and C221Y. Similarly, in Group P, there was one case
of each of the following mutations: F41C, A45V, P49L, Q54L,
P62L, I92T, L98V, T140S, A157V, W182stop, and S204R.
An L21S mutation was detected in Groups P (n=2) and C (n=
2), and R24Q and P203R mutations were found in Groups
P (n=1) and C (n=1) (Figs. 3, 4).
Entire amino acid changes in both groups
Among these mutations, only the W172stop/L173F (P<
0.001) and A184V (P=0.002) mutation were significantly
different between the groups (data not shown).
Comparison of demographic, biochemical and clinical
characteristics between patients with and without the
W172stop/L173F mutation
We also compared patients both with and without the
W172stop/L173F mutation (Table 3). AST (P=0.035) and
ALT (P=0.009) levels were significantly lower in patients
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Fig. 3. Sequence changes in the S regions up to the front of ‘a’
determinant. An S3N mutation in Groups P (n=4) and C (n=2),
and an I68T mutation in Groups P (n=3) and C (n=1) were detect-
ed. G10stop, L15V, I28V, W36L, F41S, T47A, Q51L, N59H, C69-
stop, L87V, F93L, V96G, L97P, and G102C mutations were detect-
ed in Group C (one case each). F41C, A45V, P49L, Q54L, P62L,
I92T, and L98V mutations were identified in Group P (one case
each). An L21S mutation in Groups P (n=2) and C (n=2) and an
R24Q mutation in Groups P (n=1) and C (n=1) were detected.
Fig. 4. Sequence changes in the S regions from ‘a’ determinant. In
10 of 13 patients in Group P, sW172stop (n=5) and sL173F (n=5)
mutations were detected. A184V mutations were found in 9 of 13
patients in Group P. I126T mutations in groups P (n=4) and C (n=
1) and L213I mutations in Groups P (n=6) and C (n=1) were detect-
ed. T131P, Y200F, and C221Y mutations were detected in Group
C (one case each). T140S, A157V, W182stop, and S204R muta-
tions were identified in Group P (one case each). One P203R muta-
tion was detected in each group.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV,







Male 9 (90%) 10 (83.3%) 1.0
Age (yr) 46.5 (40-57) 41.5 (28-75) 0.155
AST (IU/L) 69.5 (23-273) 157.5 (64-385) 0.035
ALT (IU/L) 87 (22-232) 213.5 (47-325) 0.009
Bilirubin (mg/dL) 1.0 (0.4-3.1) 1.3 (0.4-33.6) 0.644
Albumin (g/dL) 4.4 (2.8-4.8) 3.9 (2.5-5.0) 0.291
HBV DNA  7.0 (4.1-8.0) 7.9 (5.8-9.2) 0.052
(log copies/mL)
HBsAg (IU/mL) 5,777  13,307 0.582
(2,010-98,440) (960-50,660)
Cirrhosis 6 (60%) 4 (33.3%) 0.231
HCC 1 (10%) 1 (8.3%) 1.0
Table 3. Comparison of demographic, biochemical and clinical
characteristics between patients with and without W172stop/
L173F mutationwith W172stop/L173F mutation. However, there was no sig-
nificant difference when the same comparison was done in
Group P alone.
Comparison of demographic, biochemical and clinical
characteristics between patients with and without the
sA184V mutation
We compared patients both with and without the sA184V
mutation (Table 4). Only the ALT level was significantly lower
in patients with the sA184V mutation (P=0.012). However,
there was no significant difference when the same compari-
son was done in Group P alone.
DISCUSSION
HBV is an enveloped virus and contains a partially double-
stranded DNA genome of approximately 3,200 base pairs (1,
3, 8). The major envelope protein of HBsAg consists of 226
amino acids and is coded by the S gene (9). The polymerase
gene overlaps all six other genes, including the three enve-
lope genes, Pre-S1, Pre-S2, and S, which encode for the large
(by the Pre-S1/S2/S gene), middle (by the Pre-S2/S gene), and
small (the S gene) envelope proteins, respectively (1, 10). Due
to the overlap between the polymerase and surface genes, the
selection of a drug-resistant HBV polymerase gene mutant may
have important clinical and diagnostic implications (1, 3). 
Deletions and mutations of overlapping surface genes have
been reported in LMV treated patients who loose HBsAg (3).
In addition to surface gene deletions and mutations, deletions
of nucleotides in the Pre-S2 region and amino acid substitu-
tions in the ‘a’ determinant region of HBsAg have been report-
ed (5). The LMV-resistant polymerase mutation, rtV173L
(sE164D), has been reported to reduce the antigenicity of
HBsAg (11). 
Drug resistant mutations to ADV have been reported main-
ly in the HBV polymerase domain D rtN236T or the domain
B rtA181V/T (1, 12). Whereas a domain D rtN236T muta-
tion does not overlap with the envelope gene, a mutation at
rtA181T can result in a stop mutation in the envelope region
of the S gene (sW172stop). In addition, an ADV-resistant
mutation at rtA181V results in a concomitant change at sL-
173F (1). Therefore, we selected LMV-resistant chronic hep-
atitis B patients who had developed ADV-resistant A181T/V
mutations during ADV rescue therapy. We sought to detect
other mutations caused by the ADV-resistant mutation and
its clinical implications. Patients who had not received antivi-
ral treatment were selected for the control group. 
In the present study, biochemical data showed that AST,
ALT and total bilirubin levels were higher in Group C. And
it can be considered that Group C has relatively worse bio-
chemical level. One limitation should be noted: we used indi-
rect markers or surrogates of liver function in the biochemi-
cal tests and fibrosis, proliferation, apoptosis, and other patho-
genic processes were not measured. The patients should be
followed for a long period of time and the clinical impact of
the rtA181T/V mutation should be evaluated. 
The results of our study showed that treatment induced
or naturally occurring mutations of the Pre-S1, Pre-S2, and
surface antigen regions were detected in most of the patients
studied. In Group P, although statistically insignificant, Pre-
S1 region nucleotide deletions at position ‘59’, and mutations
V60A and L74I were the primary changes detected. Five pati-
ents carrying Pre-S2 start codon mutations had either cirrho-
sis or HCC. In addition, V32A, I45T, and T49I mutations
at Pre-S2 were detected in the HCC patients only. An F46S
mutation in the Pre-S2 region was detected only in patients
with the ADV-resistant rtA181T/V mutation. These results
are consistent with a number of previous reports indicating
that Pre-S mutations are associated with advanced liver dis-
ease and active viral replication (13-19). In Group C, a num-
ber of point mutations were detected. A similar pattern of
mutations was also detected in Group P. There were no spe-
cific mutations confined to the Pre-S2 region in Group C.
Nucleotide 21 deletions were frequently observed in both
Groups P and C, and nucleotide 30 deletions were observed
in all but four cases. We are uncertain as to what caused the
sequence changes. It is difficult to suggest that the sequence
changes were caused by resistant mutations because these dele-
tions were more common in Group C. The development of
Pre-S deletion mutants depends on HBV genotypes (20).
Recently, one report showed that Pre-S deletions were more
common in Korean HBV genotype strains and correlated
with genotype C and advanced liver disease (21). The muta-
tions in the Pre-S region, particularly the deletions, may affect
the ratio between the small and large envelope proteins, result-
ing in endoplasmic reticulum stress associated with the aggra-
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AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBV,







Male 8 (88.9%) 11 (84.6%) 1.0
Age 45 (40-57) 43 (28-75) 0.525
AST (IU/L) 65 (23-273) 125 (40-385) 0.061
ALT (IU/L) 96 (22-156) 232 (30-325) 0.012
Bilirubin (mg/dL) 1.0 (0.4-3.1) 1.3 (0.4-33.6) 0.664
Albumin (g/dL) 4.7 (2.8-5.0) 3.7 (2.5-4.8) 0.204
HBV DNA  7.5 (4.1-8.0) 7.9 (5.8-9.2) 0.171
(log copies/mL)
HBsAg (IU/mL) 6,330  8,850  0.948
(2,010-98,440) (960-50,660)
Cirrhosis 5 (55.6%) 5 (38.5%) 1.0
HCC 0 2 (15.4%) 0.494
Table 4. Comparison of demographic, biochemical and clinical
characteristics between patients with and without sA184V muta-
tionvation of liver disease (21, 22). These patients should be ob-
served closely.
The S gene mutation, A184V, was detected in the ADV-
resistant rtA181T/V polymerase mutation group alone. This
mutation site overlaps with the rt192 region in the polymerase
gene. However, the A184V mutation did not result in amino
acid changes in the polymerase region. There is one publish-
ed report that the A184V mutation was related to reduced or
negative HBsAg signal (23). In our study, however, changes
in HBsAg titer were not observed. When compared with
patients who have not A184V mutation including Group
C, ALT level alone was significantly lower in patients with
A184V mutation. But it is difficult to conclude that it is
caused by A184V mutation, because this difference was no
longer significant when the analysis was done in pure Group
P and patient’s number was not enough. The clinical impli-
cations of this remain to be determined. Of all mutations
within the ‘a’ determinant region of HBsAg, the most com-
mon antigenic determinant mutations are in amino acids 124
to 147 (24). Substitutions within the ‘a’ loop can create a puta-
tive glycosylation site in mutant HBVs that result in unde-
tectable HBsAg antigenicity (25). In our study, an I126T
mutation was detected in 4 of 13 ADV mutants and one of
nine control cases. One case of a T131P mutation in Group
C and one case of a T140S mutation in Group P were also
detected. Some investigators have reported that s126 threo-
nine is a wild type variant and nucleotide substitution of thre-
onine has no specific effect (26-29). To determine the clini-
cal significance of I126T, T131P, and T140S mutations, fur-
ther studies are required. It is possible that these amino acid
substitutions were caused by a remaining LMV-resistant muta-
tion, though a rtM204I/V mutation was not detected in se-
quencing analysis.
Although surface gene mutations were common in Group
P, serum HBsAg titers were not significantly different from
those of Group C. Despite the fact that we did not measure
in vitro hepatitis B surface antigen production, the impact
of coexisting wild type virus, viral replication, fitness, pack-
aging, and antigenic targets for immunoassay should be con-
sidered. Full-length HBV genomes should be cloned and the
S gene should be sequenced and analyzed. It should be noted
that, in this study, patients who were nucleoside treatment-
naive controls had a variety of Pre-S gene mutations as well
as surface gene mutations.
We detected sW172stop and sL173F mutations in 10 of
the 13 patients with ADV-resistant rtA181T/V polymerase
mutations. A large percentage of the cases with rtA181T
mutations developed sW172stop mutations. In cases with
ADV treated LMV-resistant mutations, the rtA181T muta-
tion was reported at the ADV treatment baseline with low
HBV DNA titers (30). 
In conclusion, the results of this study showed that treat-
ment-induced or naturally occurring mutations of the Pre-
S1, Pre-S2 and surface antigen regions were frequent. The
sA184V mutation was detected in the A181T/V polymerase
mutation group alone. Although sW172stop and sL173F
mutations were detected in the polymerase mutation group,
a reduction in HBsAg titer was not found. Further study is
needed to determine the clinical implications of viral repli-
cation, topographic alteration, fitness, envelope gene produc-
tion, and interaction with wild type HBV DNA.
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